drugset / Trial / NCT05298449
Phase 2 of HU-045 in Glabellar Lines
RandomizedParallel-groupDouble-blindTreatment
Summary
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines
Timeline
- Start
- 2022-03-28
- Primary completion
- 2022-11-07
- Completion
- 2023-04-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Botulinum toxin type A | Protein / enzyme biologic | 4 iu | Intramuscular |
Indications
No indication recorded.